Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Gastrointestinal Stromal Tumors 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Melanoma 2Leukemia 2Burkitt Lymphoma 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Neoplasm, Residual 1Myeloproliferative Disorders 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Hypereosinophilic Syndrome 1Hematologic Diseases 1Head and Neck Neoplasms 1Digestive System Neoplasms 1Desmoid Tumors 1Dermatofibrosarcoma 1Congenital Bone Marrow Failure Syndromes 1Chordoma 1Carcinoma, Adenoid Cystic 1Blast Crisis 1

Interventions

venetoclax 1ruxolitinib 1pevonedistat 1Imatinib Mesylate 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypereosinophilic Syndrome × Imatinib Mesylate × 90 days × Clear all
NCT00044304 2026-03-16

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
70 enrolled
Myeloid

Hypereosinophilic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡